Inhibikase Therapeutics (IKT) News
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.32+0.02 (+1.54%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IKT news summary
We found 2 recent headlines mentioning Inhibikase Therapeutics (IKT): 0 in the past week and 1 in the past 30 days, most often from GlobeNewswire. For price context, IKT is up 1.54% at $1.32. The most recent story, "Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Inhibikase Therapeutics headlines
- Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent ActivityWILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…GlobeNewswire
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of DirectorsWILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel…GlobeNewswire